AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 191 min read$LLY

Lilly's Omvoh Meets Primary Endpoint In Phase 3 Pediatric Ulcerative Colitis Study

Eli Lilly (LLY) reported positive Phase 3 trial results for Omvoh in pediatric ulcerative colitis, meeting its primary endpoint. 50% of patients achieved clinical remission at one year. The company plans to submit results to regulators for potential label expansion. LLY stock closed at $1257.03 on October 16, 2026, and was down 1.05% in pre-market trading.

Original reporting
rttnews.com
Published Oct 19, 2026, 9:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 9:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lilly's Omvoh Meets Primary Endpoint In Phase 3 Pediatric Ulcerative Colitis Study — source image
Source · rttnews.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The data could expand Omvoh's label, increasing revenue potential and supporting a higher valuation for LLY.

02

Market read

First‑report trial data may drive short‑term stock movement and longer‑term valuation shifts for Eli Lilly and the biotech sector.

03

What to watch

Competition from other IL‑23 inhibitors and the need for long‑term safety data could temper upside.

Relevance 7/10Novelty 9/10Timing: pre‑market today

Background

Eli Lilly announced Phase 3 pediatric ulcerative colitis results at the UEG Week Congress, marking the first one‑year data for an IL‑23p19 inhibitor in this indication.

Company-level read

Ticker impact

$LLYBullishMedium confidence
Context

Phase 3 pediatric ulcerative colitis trial met primary endpoint, suggesting potential label expansion and upside for Eli Lilly.

Expected impact

likely upward pressure as market anticipates regulatory approval for pediatric indication

Evidence & confidence

The SHINE-2 study showed 50% remission at week 52 and strong safety, a first for an IL‑23p19 inhibitor in this population, which may drive a price rally.

Market effects

Sector

May boost biotech sector focused on inflammatory‑bowel disease therapies.

Regional

US biotech stocks could see modest gains.

Global

Potentially influences global IBD drug pipeline valuations.

Counterpoint

What could challenge this read

If regulatory hurdles remain high, the market may have already priced in the data.

Key entities

  • company
    Eli Lilly and Company

    Pharmaceutical company developing Omvoh (mirikizumab).

  • drug
    Omvoh (mirikizumab)

    IL‑23p19 inhibitor approved for adult ulcerative colitis, now showing pediatric efficacy.

Read at source← All news

StoryEli Lilly reports Phase 3 SHINE‑2 trial shows 81% response and 50% remission in pediatric ulcerative colitis

Related articles

OCT 19
$LLYMed

Your Questions Answered: Foundayo’s EU Panel Backing, Enspryng for TED, Gilead’s Masked TCE Bet, FDA’s Rare Disease Overhaul, and More

Eli Lilly's Foundayo received a positive CHMP opinion for EU marketing authorization for weight management and type 2 diabetes. Roche's Enspryng gained FDA approval for thyroid eye disease. AstraZeneca partnered with insitro for AI-driven drug discovery in MASH and cardiomyopathies. The FDA launched a Rare Disease Framework Initiative to improve drug development for rare diseases. Gilead and Vir Biotechnology agreed to a $1.87 billion collaboration for masked T-cell engagers.

pharmexec.com3 min
OCT 19
$LLYHigh

Eli Lilly (LLY) Reports Positive Phase 3 SHINE-2 Trial Results f

Eli Lilly (LLY) reported positive Phase 3 SHINE-2 trial results for Omvoh in pediatric ulcerative colitis, showing 81% clinical response and 50% remission rates. The company's GF Value™ suggests a 20.4% undervaluation, with a GF Score™ of 96/100. Insider selling totaled $2.66 billion over 12 months, while 25 gurus hold the stock with balanced activity. LLY's P/E ratio is 42.71x, below its 5-year median of 53.19x.

gurufocus.com2 min
OCT 19
$LLYMed

Lilly reports positive pediatric ulcerative colitis trial data

Eli Lilly (NYSE:LLY) reported that its drug Omvoh met the primary endpoint in a Phase 3 study for pediatric ulcerative colitis. The SHINE-2 study showed 81% of patients achieved clinical response at Week 12, with 50% of responders in clinical remission at Week 52. The company plans to submit the data to global regulators for potential label expansion. Omvoh is already approved for adults in 47 countries.

investing.com2 min
OCT 19
$LLYHigh

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Eli Lilly's Omvoh (mirikizumab-mrkz) met the primary endpoint of clinical remission in a Phase 3 study for pediatric ulcerative colitis, with 50% of responders achieving remission at one year. The company plans to submit these data to regulators for potential label expansion. Omvoh is currently approved for adults with the condition.

prnewswire.com2 min
OCT 19
$LLYHigh

At Week 12, 81% of children in Lilly's ulcerative colitis trial responded to treatment

Lilly reported positive results from its SHINE-2 trial, showing 81% of pediatric ulcerative colitis patients responded to Omvoh (mirikizumab) treatment. Key outcomes included 50% clinical remission and 50% corticosteroid-free remission. Lilly plans to submit these data to regulators for potential label expansion. Omvoh is currently approved for adults with ulcerative colitis.

stocktitan.net2 min